NewLink Genetics Corporation’s (NLNK) “Buy” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their buy rating on shares of NewLink Genetics Corporation (NASDAQ:NLNK) in a research report report published on Friday. They currently have a $26.00 target price on the biotechnology company’s stock.

“Incremental Data Points in the Right Direction. Updated data from the Phase I/II trial in advanced melanoma (excluding ocular melanoma), showed improving complete responses (CRs) to 20% vs. 12% reported at six months. The overall response rate (ORR) and disease control rate (DCR) were stable at 61% and 80%, respectively, vs. 59% and 80% at six months.”,” the firm’s analyst commented.

A number of other research analysts also recently commented on NLNK. Jefferies Group LLC reissued a hold rating and issued a $18.00 price target on shares of NewLink Genetics Corporation in a report on Monday, May 15th. ValuEngine raised NewLink Genetics Corporation from a sell rating to a hold rating in a report on Friday, May 19th. Robert W. Baird reaffirmed an outperform rating and set a $25.00 target price on shares of NewLink Genetics Corporation in a report on Monday, June 5th. Finally, Zacks Investment Research raised NewLink Genetics Corporation from a hold rating to a buy rating and set a $12.00 target price on the stock in a report on Wednesday, June 7th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. NewLink Genetics Corporation currently has an average rating of Buy and an average target price of $24.17.

NewLink Genetics Corporation (NLNK) opened at 16.64 on Friday. NewLink Genetics Corporation has a 52-week low of $5.90 and a 52-week high of $25.17. The firm’s 50-day moving average price is $7.52 and its 200 day moving average price is $12.81. The firm’s market cap is $489.57 million.

NewLink Genetics Corporation (NASDAQ:NLNK) last issued its quarterly earnings results on Friday, July 28th. The biotechnology company reported ($0.57) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.21. The firm had revenue of $10.37 million during the quarter, compared to the consensus estimate of $2.65 million. NewLink Genetics Corporation had a negative return on equity of 55.03% and a negative net margin of 161.94%. On average, equities research analysts forecast that NewLink Genetics Corporation will post ($2.82) EPS for the current year.

TRADEMARK VIOLATION WARNING: “NewLink Genetics Corporation’s (NLNK) “Buy” Rating Reiterated at Cantor Fitzgerald” was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/09/12/newlink-genetics-corporations-nlnk-buy-rating-reiterated-at-cantor-fitzgerald.html.

A number of large investors have recently added to or reduced their stakes in the business. Eqis Capital Management Inc. lifted its holdings in NewLink Genetics Corporation by 0.6% during the 2nd quarter. Eqis Capital Management Inc. now owns 32,999 shares of the biotechnology company’s stock worth $243,000 after buying an additional 183 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in NewLink Genetics Corporation by 3.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after buying an additional 556 shares during the last quarter. Advisor Group Inc. lifted its holdings in NewLink Genetics Corporation by 3.4% during the 2nd quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock worth $133,000 after buying an additional 600 shares during the last quarter. American International Group Inc. lifted its holdings in NewLink Genetics Corporation by 7.1% during the 1st quarter. American International Group Inc. now owns 13,321 shares of the biotechnology company’s stock worth $321,000 after buying an additional 880 shares during the last quarter. Finally, Northwest Wealth Management LLC lifted its holdings in NewLink Genetics Corporation by 3.1% during the 2nd quarter. Northwest Wealth Management LLC now owns 58,022 shares of the biotechnology company’s stock worth $426,000 after buying an additional 1,740 shares during the last quarter. 54.78% of the stock is currently owned by institutional investors.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply